Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 423129, 9 pages
Research Article

An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo

1Department of Biology, Liaoning Medical University, Jinzhou 121001, China
2Institute of Psychology, Chinese Academy of Sciences, Beijing 100101, China
3Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, China
4Institute of Osteosarcoma, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China
5Educational Technologies and Simulation Training Centre, Naval University of Engineering Tianjin Campus, Tianjin 300450, China
6Shanghai Junshi Biosciences Inc., Shanghai 201203, China
7Central Research Laboratory, Jilin University Bethune Second Hospital, Changchun 130041, China
8Department of Gynecology and Obstetrics, General Hospital of Chinese Armed Police, Beijing 100039, China

Received 23 January 2013; Revised 14 April 2013; Accepted 15 April 2013

Academic Editor: José Luis Ríos

Copyright © 2013 Lihua Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Arginine is a semiessential amino acid required for the growth of melanoma and hepatocellular carcinoma, and the enzymatic removal of arginine by pegylated arginine deiminase (ADI) or arginase is being tested clinically. Here, we report a genetically engineered arginase FC fusion protein exhibiting a prolonged half-life and enhanced efficacy. The use of this enzyme to treat different tumor lines both inhibited cell proliferation and impaired cellular migration in vitro and in vivo. Our data reinforce the hypothesis that nutritional depletion is a key strategy for cancer treatment.